Drug details

Ongentys (opicapone capsules)

type of Antiparkinson Agents, COMT Inhibitors

Ongentys (opicapone) is a catechol-O-methyltransferase (COMT) inhibitor used as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes.

The following drugs are related to Ongentys, either as a replacement or used together:

• Gocovri (amantadine extended release capsules, for oral use)
• Apokyn (apomorphine)
• Kynmobi (apomorphine hydrochloride sublingual film)
• Azilect (rasagiline)
• Cogentin (benztropine mesylate injection)
• Parlodel (bromocriptine mesylate)
• Rytary (carbidopa and levodopa capsules)
• Duopa (carbidopa and levodopa enteral suspension)
• Parcopa (carbidopa and levodopa extended-release tablets)
• Stalevo (carbidopa, levodopa and entacapone)
• Sinemet (carbidopa-levodopa)
• Sinemet CR (carbidopa-levodopa sustained release)
• Comtan (entacapone)
• Eldepryl (selegiline hcl)
• Exelon (rivastigmine tartrate)
• Exelon Patch (rivastigmine transdermal system)
• Inbrija (levodopa inhalation powder)
• Nourianz (istradefylline tablets)
• Mirapex (pramipexole)
• Mirapex ER (pramipexole dihydrochloride extended-release tablets)
• Neupro (rotigotine transdermal system)
• Requip (ropinirole hcl)
• Requip XL (ropinirole extended release tablets)
• Xadago (safinamide tablets)
• Zelapar (selegiline hydrochloride)
• Tasmar (tolcapone)